DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Ph II Study Examining Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation &/or Chemotherapy

Information source: Barbara Ann Karmanos Cancer Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Head and Neck Cancer

Intervention: capecitabine (Drug); Surgery, chemotherapy and/or radiotherapy (Procedure)

Phase: Phase 2

Status: Completed

Sponsored by: Barbara Ann Karmanos Cancer Institute

Official(s) and/or principal investigator(s):
George H. Yoo, MD, Study Chair, Affiliation: Barbara Ann Karmanos Cancer Institute

Summary

RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving capecitabine after surgery, radiation therapy, and/or chemotherapy may kill any remaining tumor cells. PURPOSE: This phase II trial is studying how well capecitabine works in treating patients who have undergone previous surgery, radiation therapy, and/or chemotherapy for head and neck cancer.

Clinical Details

Official title: A Phase II Study Examining the Feasibility of Long Term and Low Dose Oral Capecitabine (Xeloda®) in Newly Diagnosed Head and Neck Squamous Cell Carcinoma (HNSCC) After Surgery, Radiation and/or Chemotherapy

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Feasibility of Treatment as Assessed.

Secondary outcome:

Time to Recurrence

Local-regional Control Rate Occurrence

Survival Rate

Incidence of Second Primary Tumor Occurrence

Detailed description: OBJECTIVES: Primary

- Determine the feasibility of adjuvant low-dose capecitabine in patients with squamous

cell carcinoma of the head and neck who have undergone prior curative surgery, radiotherapy, and/or chemotherapy. Secondary

- Determine the time to recurrence, local-regional control, and survival rate in patients

treated with this drug.

- Determine the incidence of second primary tumors in patients treated with this drug.

OUTLINE: This is an open-label study. Patients receive oral capecitabine once daily for 1 year in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 1 year. PROJECTED ACCRUAL: A total of 41 patients will be accrued for this study.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

DISEASE CHARACTERISTICS:

- Histologically confirmed squamous cell carcinoma of the head and neck, including 1 of

the following primary tumor sites:

- Oral cavity

- Oropharynx

- Nasopharynx

- Hypopharynx

- Larynx

- Unknown primary

- Any disease stage allowed

- No evidence of active disease

- Must have undergone curative surgical resection, radiotherapy, and/or chemotherapy at

least 1 month, but no more than 4 years ago PATIENT CHARACTERISTICS: Performance status

- Karnofsky 70-100%

Life expectancy

- More than 3 months

Hematopoietic

- White blood count (WBC) ≥ 3,000/mm^3

- Granulocyte count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

Hepatic

- Bilirubin ≤ 1. 5 times upper limit of normal (ULN)

- Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≤ 2. 5 times ULN

- Alkaline phosphatase ≤ 2. 5 times ULN

- Hepatitis B and/or C negative

Renal

- Creatinine clearance > 50 mL/min

Cardiovascular

- No myocardial infarction within the past 12 months

- No uncontrolled congestive heart failure

- No unstable or uncontrolled angina

Gastrointestinal

- No lack of physical integrity of the upper gastrointestinal tract

- Must be able to swallow tablet

- No malabsorption syndrome

Other

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- HIV negative

- No other malignancy within the past 5 years except adequately treated basal cell or

squamous cell skin cancer, carcinoma in situ of the cervix, or stage I or II cancer for which the patient is currently in complete remission

- No history of uncontrolled seizures, central nervous system (CNS) disorders, or

psychiatric disability that would preclude study compliance or giving informed consent

- No ongoing postoperative fistula

- No prior unanticipated severe reaction to fluoropyrimidine therapy or known

sensitivity to fluorouracil

- No other serious uncontrolled medical or surgical condition that would preclude study

participation PRIOR CONCURRENT THERAPY: Chemotherapy

- See Disease Characteristics

- Prior oral fluoropyrimidine therapy allowed provided it was given in the adjuvant

setting and completed ≥ 12 months ago Radiotherapy

- See Disease Characteristics

Surgery

- See Disease Characteristics

- More than 4 weeks since prior major surgery and recovered

- No prior organ allografts

Other

- More than 4 weeks since prior participation in any investigational drug study

Locations and Contacts

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan 48201-1379, United States
Additional Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Starting date: December 2003
Last updated: January 15, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017